Gilead's FDA-approved Bixlenvo (BIC/LEN), a grain-of-rice-sized once-daily HIV pill, targets virologically suppressed ...
FDA approves Roivant's Lisraya (brepocitinib), first oral drug for dermatomyositis; TD Cowen sees $5B–$10B potential across ...
Fifth Circuit rejects PhRMA's challenge to Medicare drug-price negotiation, ending pharma's first wave of IRA litigation.
Amgen's Tezspire and Biokin's ADC post Phase 3 wins; Takeda exits China gene therapy deal; Gates Foundation backs ProFound on ...
Metriport raises $26M Series A led by Matrix to help doctors retrieve and prioritize patient data from across health systems.
Is it the right call for Eli Lilly to stop disclosing its Phase 1 pipeline? Analysts and former Lilly execs weigh in.
MassBio report shows MA biopharma jobs fell 3.1%, NIH awards dropped 6%, while China's drug pipeline grew 36% in 2025, ...
South Korea-based SK Biopharmaceuticals has offered up to $795 million for the global rights to Biohaven’s Kv7 ion channel ...
Haisco licenses inflammatory drug to Sentivera for $40M upfront, $36M stock, $1.46B milestones; FDA OKs ViiV's dolutegravir ...
Akeso and its partner Summit Therapeutics proclaimed on Tuesday that their high-profile PD-1xVEGF bispecific hit a major ...
Sword Health is acquiring mental health startup Headspace in a cash deal effective Sept. 14, uniting two digital health ...
Haisco Pharma partners with ARCH Venture's Bob Nelsen & Population Health Partners' Clive Meanwell to launch Sentivera in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results